Evidence map›Paper›PMID 36959570›Full record

ArticleBMC microbiology2023

Multidrug-resistant Aeromonas bacteria prevalence in Nile tilapia broodstock.

Ahmed H Sherif, Amina S Kassab

Open access · goldFull text read
In one paragraph

Article in BMC microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Integrated Probiotic Benefits ofAntioxidants (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Pathogens (Basel, Switzerland) · 2025
    Article
  11. Review
  12. Article
  13. Impact of repeatedFrontiers in microbiology · 2025
    Article
  14. Article
  15. Immune response and bacterial resistance ofOpen veterinary journal · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Cross-sectional analysis of risk factors associated withFrontiers in cellular and infection microbiology · 2024
    Article
  20. First Report ofPathogens (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ahmed H SherifFish Disease Department, Animal Health Research Institute AHRI, Agriculture Research Center ARC, Kafrelsheikh, Egypt. ahsherif77@yahoo.com.
Amina S KassabFish Disease Department, Animal Health Research Institute AHRI, Agriculture Research Center ARC, Kafrelsheikh, Egypt.
Animal Health Research Institute · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAeromonas hydrophila is an opportunistic pathogen. Thus, it has received significant attention mainly in the fish sectors with high production scales. Nile tilapia broodstock confined in the environment of fish hatcheries can be stressed. Hence, they are vulnerable to A. hydrophila.

resultsSequencing of the gyr B gene revealed the presence of 18 different A. hydrophila strains (kdy 10,620-10,637), which were deposited in the NCBI under accession numbers ON745861-ON745878. The median lethal doses of the isolates ranged from 2.62 × 10

conclusionsNile tilapia broodstock, mortality is associated with different A. hydrophila strains, which harbored virulent and MDR genes. Furthermore, TiO

Indexed as

AeromonasCichlidsFish DiseasesGram-Negative Bacterial InfectionsAeromonas hydrophilaAnimalsAnti-Bacterial AgentsEnterotoxinsHemolysin ProteinsPrevalenceTitaniumAnti-Bacterial AgentsEnterotoxinsHemolysin ProteinsTitaniumtitanium dioxideNile tilapia; Multidrug resistant; Aeromonas bacteria; Hatcheries

Identifiers

PMID36959570
PMCPMC10037768
OpenAlexW4360804479

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read148
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.